StemCyte announced a major breakthrough in the development of its umbilical cord blood cell therapy REGENECYTE for the treatment of long COVID syndrome. The company has successfully completed an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) regarding its Phase III pivotal trial design and Biologics License Application (BLA) pathway. On March 28, 2025, StemCyte received the official meeting minutes from the FDA, which expressed a positive response to the proposed clinical design and planning for the Phase III pivotal trial targeting long COVID.

During the EOP2 meeting, StemCyte and the FDA discussed critical topics including clinical data, chemistry, manufacturing, and controls (CMC), as well as the Phase III trial design. The FDA highly endorsed the Phase II clinical data of REGENECYTE and provided constructive suggestions for the clinical trial design, confirming the overall direction and planning of the pivotal Phase III study. Based on the feedback, StemCyte will accelerate the trial’s progress and plans to initiate the Phase III trial ahead of schedule, significantly reducing the time to market for REGENECYTE.

Thanks to the successful results and robust scientific data from the Phase II trial, the FDA offered positive guidance on the Phase III plan, including a reduction in the number of participants and the overall trial timeline. This will allow StemCyte to significantly shorten the duration and cost of the study. Within just three years, the company has advanced REGENECYTE’s clinical development for long COVID into its final stage.

In parallel, REGENECYTE has been granted Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA. Under this designation, the FDA has also approved REGENECYTE for compassionate use in the U.S., allowing for paid treatment of long COVID. This will facilitate early revenue generation while advancing REGENECYTE’s market presence in the U.S.

With the global number of long COVID patients rising sharply, market demand for REGENECYTE is growing rapidly. According to the World Health Organization’s latest report in March 2025, over 770 million people have been diagnosed with COVID-19, and it is estimated that nearly 400 million are affected by long COVID worldwide, representing a vast market opportunity. As an innovative therapy for long COVID, REGENECYTE offers a new treatment option for patients globally and holds significant commercial potential.

StemCyte is strategically modeling its development approach on the success of Keytruda, the blockbuster cancer drug, using its FDA approval of REGENECYTE as a foundation to rapidly expand into new indications and global markets. The company is actively pursuing international partnerships and licensing opportunities, aiming to drive REGENECYTE’s global clinical development and commercialization and to establish a strong international footprint.

Resource: 僅用時三年！永笙取得突破性進展 REGENECYTE治療長新冠將進入三期臨床試驗